An Oral Administration of Cilostazol Before Focal Ischemia Reduces the Infarct Volume with Delayed Cerebral Blood Flow Increase in Rats

Journal of Stroke and Cerebrovascular Diseases

Volumn 17, Issue 5, 2008, Pages 281-286

  Yuzawa, Izumi ^a   Yamada, Masaru ^a   Fujii, Kiyotaka ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

cerebral blood flow; Cilostazol; focal cerebral ischemia; rat

Indexed keywords

CILOSTAZOL; TRIPHENYLTETRAZOLIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CIRCULATION; BRAIN DAMAGE; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; BRAIN PROTECTION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; EXPERIMENTAL MODEL; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; SCORING SYSTEM; SINGLE DRUG DOSE; STAINING; STATISTICAL SIGNIFICANCE;

ADMINISTRATION, ORAL; ANIMALS; BRAIN ISCHEMIA; CEREBROVASCULAR CIRCULATION; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; NEUROPROTECTIVE AGENTS; PHOSPHODIESTERASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; REGIONAL BLOOD FLOW; TETRAZOLES;

EID: 49849089587     PISSN: 10523057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jstrokecerebrovasdis.2008.03.007     Document Type: Article

References (20)

1. Kawamura K., Watanabe K., and Kimura Y. Effect of cilostazol, a new antithrombotic drug, on cerebral circulation. Arzneimittelforschung 35 (1985) 1149-1154
2. Kimura Y., Tani T., Kanbe T., et al. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung 35 (1985) 1144-1149
3. Yasuda K., Sakuma M., and Tanabe T. Hemodynamic effect of cilostazol on increasing peripheral blood flow in arteriosclerosis obliterans. Arzneimittelforschung 35 (1985) 1198-1200
4. Gotoh F., Tohgi H., Hirai S., et al. Cilostazol stroke preventive study: A placebo-controlled double blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis 9 (2000) 147-157
5. Lee J.H., Oh G.T., Park S.Y., et al. Cilostazol reduces atherosclerosis by inhibition of superoxide and tumor necrosis factor-alpha formation in low-density lipoprotein receptor-null mice fed high cholesterol. J Pharmacol Exp Ther 313 (2005) 502-509
6. Kwon S.U., Cho Y.J., Koo J.S., et al. Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: The multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis. Stroke 36 (2005) 782-786
7. Morishita R., Higaki J., Hayashi S.I., et al. Role of hepatocyte growth factor in endothelial regulation: Prevention of high D-glucose-induced endothelial cell death by prostaglandins and phosphodiesterase type 3 inhibitor. Diabetologia 40 (1997) 1053-1061
8. Kim K.Y., Shin H.K., Choi J.M., et al. Inhibition of lipopolysaccharide-induced apoptosis by cilostazol in human umbilical vein endothelial cells. J Pharmacol Exp Ther 300 (2002) 709-715
9. Otsuki M., Saito H., Xu X., et al. Cilostazol represses vascular cell adhesion molecule-1 gene transcription via inhibiting NF-κB binding to its recognition sequence. Atherosclerosis 158 (2001) 121-128
10. Van Uitert R.L., and Levy D.E. Regional brain blood flow in the conscious gerbil. Stroke 9 (1978) 67-72
11. Betz A.L., and Iannotti F. Simultaneous determination of regional cerebral blood flow and blood-brain glucose transport kinetics in the gerbil. J Cereb Blood Flow Metab 3 (1983) 193-199
12. Koizumi J., Yoshida Y., Nakazawa T., et al. Experimental studies of ischemic brain edema: A new experimental model of cerebral embolism in rats in which recirculation can be introduced in the ischemic area. Jpn J Stroke 8 (1986) 1-8
13. Menzies S.A., Hoff J.T., and Betz A.L. Middle cerebral artery occlusion in rats: A neurological and pathological evaluation of a reproducible model. Neurosurgery 31 (1992) 100-107
14. Dogan A., Baskaya M.K., Rao V.L., et al. Intraluminal suture occlusion of the middle cerebral artery in spontaneously hypertensive rats. Neurol Res 20 (1998) 265-270
15. Nakamura T., Houchi H., Minami A., et al. Endothelium-dependent relaxation by cilostazol, a phosphodiesterase III inhibitor, on rat thoracic aorta. Life Sci 69 (2001) 1709-1715
16. Akiyama H., Kudo S., and Shimizu T. The absorption, distribution and excretion of a new antithrombotic and vasodilating agent, cilostazol, in rat, rabbit, dog and man. Drug Res 35 (1985) 1124-1132
17. Abe T., Kazama M., Kinoshita T., et al. Phase I study of a new synthetic platelet aggregation suppressant OPC-13013. Clin Eval 13 (1985) 257-280
18. Yashiro Y., and Ohhashi T. Effects of cilostazol, a selective cyclic AMP phosphodiesterase inhibitor on isolated rabbit spinal arterioles. Jpn J Physiol 52 (2002) 471-477
19. Omi H., Okayama N., Shimizu M., et al. Cilostazol inhibits high glucose-mediated endothelial-neutrophil adhesion by decreasing adhesion molecule expression via NO production. Microvasc Res 68 (2004) 119-125
20. Nishio Y., Kashiwagi A., Takahara N., et al. Cilostazol, a cAMP phosphodiesterase inhibitor, attenuates the production of monocyte chemoattractant protein-1 in response to tumor necrosis factor-alpha in vascular endothelial cells. Horm Metab Res 29 (1997) 491-495